A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
Top Cited Papers
Open Access
- 1 September 2013
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 3 (9), 1020-1029
- https://doi.org/10.1158/2159-8290.cd-13-0226
Abstract
Despite the impressive clinical activity of the second-generation antiandrogens enzalutamide and ARN-509 in patients with prostate cancer, acquired resistance invariably emerges. To identify the molecular mechanisms underlying acquired resistance, we developed and characterized cell lines resistant to ARN-509 and enzalutamide. In a subset of cell lines, ARN-509 and enzalutamide exhibit agonist activity due to a missense mutation (F876L) in the ligand-binding domain of the androgen receptor (AR). AR F876L is sufficient to confer resistance to ARN-509 and enzalutamide in in vitro and in vivo models of castration-resistant prostate cancer (CRPC). Importantly, the AR F876L mutant is detected in plasma DNA from ARN-509–treated patients with progressive CRPC. Thus, selective outgrowth of AR F876L is a clinically relevant mechanism of second-generation antiandrogen resistance that can potentially be targeted with next-generation antiandrogens. Significance: A missense mutation in the ligand-binding domain of the androgen receptor F876L confers resistance to the second-generation antiandrogens enzalutamide and ARN-509 in preclinical models of AR function and prostate cancer and is detected in plasma DNA from ARN-509–treated patients with progressive disease. These results chart a new path for the discovery and development of next-generation antiandrogens that could be coupled with a blood-based companion diagnostic to guide treatment decisions. Cancer Discov; 3(9); 1020–9. ©2013 AACR. See related commentary by Nelson and Yegnasubramanian, p. 971 This article is highlighted in the In This Issue feature, p. 953Keywords
Other Versions
This publication has 26 references indexed in Scilit:
- Targeted Next-generation Sequencing of Advanced Prostate Cancer Identifies Potential Therapeutic Targets and Disease HeterogeneityEuropean Urology, 2013
- Overcoming mutation-based resistance to antiandrogens with rational drug designeLife, 2013
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyThe New England Journal of Medicine, 2012
- The mutational landscape of lethal castration-resistant prostate cancerNature, 2012
- Androgen receptor gene polymorphisms and alterations in prostate cancer: Of humanized mice and menMolecular and Cellular Endocrinology, 2012
- Mechanisms mediating androgen receptor reactivation after castrationUrologic Oncology, 2009
- Circulating mutant DNA to assess tumor dynamicsNature Medicine, 2008
- Molecular determinants of resistance to antiandrogen therapyNature Medicine, 2003
- A mutation in the ligand binding domain of the androgen receptor of human INCaP cells affects steroid binding characteristics and response to anti-androgensBiochemical and Biophysical Research Communications, 1990
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973